Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)

Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · see citing works

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works

The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism

Rubino, F., Gagner, M., Gentileschi, P., Kini, S. U., Fukuyama, S., Feng, J. J., & Diamond, E. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133117.12646.48 · Cited by 638 · see citing works

Untitled work

Gadde (2018) · doi:10.1016/j.jacc.2017.11.011 · Cited by 626 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide

Deacon, C. F., Nauck, M. A., Meier, J. J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 439 · see citing works

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398 · see citing works

Entero-Insular Axis

Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · see citing works

Liraglutide for weight management: a critical review of the evidence

Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311 · see citing works

The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones

Meek, C. L., Lewis, H. B., Reimann, F. M., Gribble, F. M., & Park, A. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 268 · see citing works

Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors1

Bollag, R. J., Zhong, Q. P. W., Phillips, P., Min, L., Zhong, L., Cameron, R. S., Mulloy, A. L., Rasmussen, H., Qin, F., Ding, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7366 · Cited by 265 · see citing works

Functional GIP Receptors Are Present on Adipocytes

Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237 · see citing works

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 237 · see citing works

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · see citing works

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · see citing works

Effects of glucose-dependent insulinotropic peptide on osteoclast function

Zhong, Q., Itokawa, T., Sridhar, S., Ding, K., Xie, D., Kang, B., Bollag, W. B., Bollag, R. J., Hamrick, M. W., Insogna, K. L., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00364.2006 · Cited by 206 · see citing works

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193 · see citing works

Gastric Inhibitory Polypeptide (GIP) Stimulated by Fat Ingestion in Man

Falko, J. M., Crockett, S. E., Cataland, S., & Mazzaferri, E. L. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-2-260 · Cited by 192 · see citing works

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · see citing works

Receptors and effects of gut hormones in three osteoblastic cell lines

Pacheco-Pantoja, E. L., Ranganath, L. R., Gallagher, J. A., Wilson, P. J., & Fraser, W. D. (2011) · BMC Physiology · doi:10.1186/1472-6793-11-12 · Cited by 173 · see citing works

Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes

Gault, V. A., Irwin, N., Green, B. D., McCluskey, J. T., Greer, B., Bailey, C. J., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2436 · Cited by 172 · see citing works

Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions

Nasteska, D., Harada, N., Suzuki, K., Yamane, S., Hamasaki, A., Joo, E., Iwasaki, K., Shibue, K., Harada, T., & Inagaki, N. (2014) · Diabetes · doi:10.2337/db13-1563 · Cited by 171 · see citing works

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158 · see citing works

First-Phase Insulin Secretion Restoration and Differential Response to Glucose Load Depending on the Route of Administration in Type 2 Diabetic Subjects After Bariatric Surgery

Salinari, S., BERTUZZI, A., Asnaghi, S., Guidone, C., Manco, M., & Mingrone, G. (2008) · Diabetes Care · doi:10.2337/dc08-1314 · Cited by 157 · see citing works

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142 · see citing works

Vaccination against GIP for the Treatment of Obesity

Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136 · see citing works

Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

Gault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 134 · see citing works

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132 · see citing works

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 127 · see citing works

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis

Pamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126 · see citing works

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 125 · see citing works

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Nissen, A., Christensen, M., Knop, F., Vilsbøll, T., Holst, J., & Hartmann, B. (2014) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2014-2547 · Cited by 122 · see citing works

Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets

Bailey, C. J., Flatt, P. R., Kwasowski, P., Powell, C. J., & Marks, V. (1986) · European Journal of Endocrinology · doi:10.1530/acta.0.1120224 · Cited by 116 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality

Mieczkowska, A., Irwin, N., Flatt, P. R., Chappard, D., & Mabilleau, G. (2013) · Bone · doi:10.1016/j.bone.2013.07.003 · Cited by 115 · see citing works

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 111 · see citing works

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

Torekov, S. S., Harsløf, T., Rejnmark, L., Eiken, P., Jensen, J. B., Herman, A. P., Hansen, T. F., Pedersen, O. B., Holst, J. J., & Langdahl, B. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3766 · Cited by 109 · see citing works

Therapeutic potential for GIP receptor agonists and antagonists

Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105 · see citing works

Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis

Faivre, É., Gault, V. A., Thorens, B., & Hölscher, C. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00866.2010 · Cited by 104 · see citing works

Characterization of the Cellular and Metabolic Effects of a Novel Enzyme-Resistant Antagonist of Glucose-Dependent Insulinotropic Polypeptide

Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 103 · see citing works

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

Gault, V. A., Parker, J. C., Harriott, P., Flatt, P. R., & O'Harte, F. P. M. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750525 · Cited by 103 · see citing works

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

Widenmaier, S. B., Kim, S. J., Yang, G. K., Reyes, T. D. L., Nian, C., Asadi, A., Seino, Y., Kieffer, T. J., Kwok, Y. N., & McIntosh, C. H. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009590 · Cited by 102 · see citing works

Gastric Inhibitory Polypeptide Release after Oral Glucose: Relationship to Glucose Intolerance, Diabetes Mellitus, and Obesity

Salera, M., Giacomoni, P., Pironi, L., Cornia, G. L., Capelli, M., Marini, A. M., Benfenati, F., Miglioli, M., & Barbara, L. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-2-329 · Cited by 101 · see citing works

Abnormalities of GIP in Spontaneous Syndromes of Obesity and Diabetes in Mice

Flatt, P. R., Bailey, C. J., Kwasowski, P., Swanston-Flatt, S. K., & Marks, V. (1983) · Diabetes · doi:10.2337/diab.32.5.433 · Cited by 101 · see citing works

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 101 · see citing works

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor

Hansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13384 · Cited by 98 · see citing works

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

Gasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 98 · see citing works

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95 · see citing works

Effect of GIP and GLP-1 antagonists on insulin release in the rat

Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95 · see citing works

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors

Gabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 94 · see citing works

Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor

Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O’Brien, S., Collinson, A., Papworth, M. A., Fredin, M. F., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 86 · see citing works

Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet–Fed Mice

Joo, E., Harada, N., Yamane, S., Fukushima, T., Taura, D., Iwasaki, K., Sankoda, A., Shibue, K., Harada, T., Suzuki, K., et al. (2017) · Diabetes · doi:10.2337/db16-0758 · Cited by 86 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · see citing works

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans

Asmar, M., Tangaa, W., Madsbad, S., Hare, K. J., Astrup, A. V., Flint, A., Bülow, J., & Holst, J. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 84 · see citing works

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice

Porter, D. W., Irwin, N., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.059 · Cited by 83 · see citing works

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)

Hinke, S. A., Manhart, S., Pamir, N., Demuth, H.-U., Gelling, R. W., Pederson, R. A., & McIntosh, C. H. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00181-9 · Cited by 82 · see citing works

Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus

Mansur, S. A., Mieczkowska, A., Bouvard, B., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25033 · Cited by 82 · see citing works

GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release

Sparre‐Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 81 · see citing works

Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice

Gaudin-Audrain, C., Irwin, N., Mansur, S. A., Flatt, P. R., Thorens, B., Baslé, M. F., Chappard, D., & Mabilleau, G. (2012) · Bone · doi:10.1016/j.bone.2012.11.039 · Cited by 80 · see citing works

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response

Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71 · see citing works

GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations

Deacon, C. F., Plamboeck, A., ROSENKILDE, M. M., de Heer, J., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00577.2005 · Cited by 70 · see citing works

Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice

Naitoh, R., Miyawaki, K., Harada, N., Mizunoya, W., Toyoda, K., Fushiki, T., Yamada, Y., Seino, Y., & Inagaki, N. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.052 · Cited by 68 · see citing works

Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice

Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65 · see citing works

RS4-type resistant starch prevents high-fat diet-induced obesity via increased hepatic fatty acid oxidation and decreased postprandial GIP in C57BL/6J mice

Shimotoyodome, A., Suzuki, J. S., Fukuoka, D., Tokimitsu, I., & Hase, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00468.2009 · Cited by 65 · see citing works

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M., Vilsbøll, T., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00008 · Cited by 65 · see citing works

Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans

Asmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1933 · Cited by 61 · see citing works

A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes

Irwin, N., Green, B. D., Mooney, M. H., Greer, B., Harriott, P., Bailey, C. J., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086082 · Cited by 59 · see citing works

New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders

Irwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 59 · see citing works

GIP6–30amide contains the high affinity binding region of GIP and is a potent inhibitor of GIP1–42action in vitro

Gelling, R. W., Coy, D. H., Pederson, R. A., Wheeler, M. B., Hinke, S. A., Kwan, T., & McIntosh, C. H. S. (1997) · Regulatory Peptides · doi:10.1016/s0167-0115(97)00009-8 · Cited by 57 · see citing works

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system

Gabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & ROSENKILDE, M. M. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55 · see citing works

A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53 · see citing works

Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice

Isken, F., Pfeiffer, A. F. H., Nogueiras, R., Osterhoff, M. A., Ristow, M., Thorens, B., Tschöp, M. H., & Weickert, M. O. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00008.2008 · Cited by 51 · see citing works

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

Irwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49 · see citing works

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

Pathak, V., Gault, V. A., Flatt, P. R., & Irwin, N. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.025 · Cited by 49 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids

Gögebakan, Ö., Andres, J., Biedasek, K., Mai, K., Kühnen, P., Krude, H., Isken, F., Rudovich, N. N., Osterhoff, M. A., Kintscher, U., et al. (2011) · Diabetes · doi:10.2337/db10-0902 · Cited by 49 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption

Mabilleau, G., Perrot, R., Mieczkowska, A., Boni, S., Flatt, P. R., Irwin, N., & Chappard, D. (2016) · Bone · doi:10.1016/j.bone.2016.07.014 · Cited by 49 · see citing works

(Pro3)GIP[mPEG]: novel, long‐acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity‐diabetes (diabesity) therapy

McClean, P. L., Irwin, N., Hunter, K., Gault, V. A., & Flatt, P. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.317 · Cited by 48 · see citing works

Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain

Ugleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E., Jørgensen, S. M., Kissow, H., Nytofte, N., Poulsen, S. S., ROSENKILDE, M. M., Seino, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311779 · Cited by 48 · see citing works

Wheat-derived arabinoxylan oligosaccharides with bifidogenic properties abolishes metabolic disorders induced by western diet in mice

Neyrinck, A. M., Hiel, S., Bouzin, C., Garcia‐Campayo, V., Cani, P. D., Bindels, L. B., & Delzenne, N. M. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-018-0019-z · Cited by 48 · see citing works

Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties

Mabilleau, G., Mieczkowska, A., Irwin, N., Simon, Y., Audran, M., Flatt, P. R., & Chappard, D. (2014) · Bone · doi:10.1016/j.bone.2014.02.013 · Cited by 47 · see citing works

Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?

Flatt, P. R. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.034 · Cited by 47 · see citing works

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41 · see citing works

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

Irwin, N., McClean, P. L., Patterson, S., Hunter, K., & Flatt, P. R. (2008) · Biological Chemistry · doi:10.1515/bc.2009.002 · Cited by 41 · see citing works

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide

Irwin, N., Clarke, G. C., Green, B. D., Greer, B., Harriott, P., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.013 · Cited by 40 · see citing works

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

Irwin, N., Hunter, K., Frizzell, N., & Flatt, P. R. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.11.007 · Cited by 38 · see citing works

Gastric inhibitory polypeptide receptor antagonist, SKL‐14959, suppressed body weight gain on diet‐induced obesity mice

Nakamura, T., Tanimoto, H., Mizuno, Y., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2018) · Obesity Science & Practice · doi:10.1002/osp4.164 · Cited by 38 · see citing works

GIP-induced vasodilation in human adipose tissue involves capillary recruitment

Asmar, M., Asmar, A., Simonsen, L., Dela, F., Holst, J. J., & Bülow, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0144 · Cited by 37 · see citing works

Insulin Action in the Double Incretin Receptor Knockout Mouse

Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G. B., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0704 · Cited by 36 · see citing works

Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide

Irwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.729 · Cited by 32 · see citing works

Dietary supplementation with hydroxypropyl-distarch phosphate from waxy maize starch increases resting energy expenditure by lowering the postprandial glucose-dependent insulinotropic polypeptide response in human subjects

Shimotoyodome, A., Suzuki, J. S., Kameo, Y., & Hase, T. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114510005854 · Cited by 29 · see citing works

Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight

Szalowska, E., Meijer, K., Kloosterhuis, N., Razaee, F., Priebe, M. G., & Vonk, R. J. (2011) · Peptides · doi:10.1016/j.peptides.2011.02.011 · Cited by 29 · see citing works

Active immunization against (Pro 3 )GIP improves metabolic status in high‐fat‐fed mice

Montgomery, I. A., Irwin, N., & Flatt, P. R. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01228.x · Cited by 27 · see citing works

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9–39)amide in obese diabetic (ob/ob) mice

Parker, J. C., Irwin, N., Lavery, K. S., Green, B. D., O'Harte, F. P. M., Gault, V. A., & Flatt, P. R. (2007) · Biological Chemistry · doi:10.1515/bc.2007.024 · Cited by 26 · see citing works

Two novel glucagon receptor antagonists prove effective therapeutic agents in high‐fat‐fed and obese diabetic mice

O'Harte, F. P. M., Franklin, Z. J., & Irwin, N. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12360 · Cited by 26 · see citing works

Glucose-dependent insulinotropic polypeptide is required for moderate high-fat diet- but not high-carbohydrate diet-induced weight gain

Maekawa, R., Ogata, H., Murase, M., Harada, N., Suzuki, K., Joo, E., Sankoda, A., Iida, A., Izumoto, T., Tsunekawa, S., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00352.2017 · Cited by 26 · see citing works

Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists

O'Harte, F. P. M., Franklin, Z. J., Rafferty, E. P., & Irwin, N. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.014 · Cited by 25 · see citing works

Biological and functional characteristics of a novel low–molecular weight antagonist of glucose‐dependent insulinotropic polypeptide receptor, SKL‐14959, in vitro and in vivo

Nakamura, T., Tanimoto, H., Mizuno, Y., Tsubamoto, Y., & Noda, H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01555.x · Cited by 25 · see citing works

Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide

Kerr, B. D., Flatt, A. J., Flatt, P. R., & Gault, V. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.077 · Cited by 25 · see citing works

Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor

Koenitzer, J. D., Pramanick, S., Pan, Q., Augustin, R., Bandholtz, S., Harriman, W. D., & Izquierdo, S. M. (2017) · mAbs · doi:10.1080/19420862.2016.1276683 · Cited by 25 · see citing works

Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells

Al‐Sabah, S., Al-Fulaij, M. A., & Ahmed, H. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.019 · Cited by 23 · see citing works

Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice

Irwin, N., Green, B. D., Gault, V. A., Cassidy, R. S., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2005) · Peptides · doi:10.1016/j.peptides.2005.08.003 · Cited by 21 · see citing works

Medium-chain triglyceride diet stimulates less GIP secretion and suppresses body weight and fat mass gain compared with long-chain triglyceride diet

Murata, Y., Harada, N., Yamane, S., Iwasaki, K., Ikeguchi, E., Kanemaru, Y., Harada, T., Sankoda, A., Shimazu‐Kuwahara, S., Joo, E., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00200.2018 · Cited by 21 · see citing works

Daily administration of the GIP‐R antagonist (Pro 3 )GIP in streptozotocin‐induced diabetes suggests that insulin‐dependent mechanisms are critical to anti–obesity‐diabetes actions of (Pro 3 )GIP

McClean, P. L., Gault, V. A., Irwin, N., McCluskey, J. T., & Flatt, P. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00712.x · Cited by 20 · see citing works

Predominant Role of GIP in the Development of a Metabolic Syndrome-like Phenotype in Female Wistar Rats Submitted to Forced Catch-up Growth

de Toro‐Martín, J., Fernández‐Millán, E., Lizárraga-Mollinedo, E., López‐Oliva, M. E., Serradas, P., Escrivá, F., & Álvarez, C. (2014) · Endocrinology · doi:10.1210/en.2013-2043 · Cited by 20 · see citing works

Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice

Perry, R., Craig, S., Ng, M., Gault, V. A., Flatt, P. R., & Irwin, N. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419875453 · Cited by 20 · see citing works

Cyclic AMP Production and Insulin Releasing Activity of Synthetic Fragment Peptides of Glucose-Dependent Insulinotropic Polypeptide

Gault, V. A., Harriott, P., Flatt, P. R., & O'Harte, F. P. M. (2002) · Bioscience Reports · doi:10.1023/a:1022073819618 · Cited by 19 · see citing works

Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets

Cassidy, R. S., Irwin, N., & Flatt, P. R. (2007) · Biological Chemistry · doi:10.1515/bc.2008.019 · Cited by 19 · see citing works

Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes

Gault, V. A., Hunter, K., Irwin, N., Greer, B., Green, B. D., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Biological Chemistry · doi:10.1515/bc.2007.019 · Cited by 19 · see citing works

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice

McShane, L. M., Franklin, Z. J., O'Harte, F. P. M., & Irwin, N. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.002 · Cited by 18 · see citing works

desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity

Irwin, N., Franklin, Z. J., & O'Harte, F. P. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.041 · Cited by 16 · see citing works

Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists

Gault, V. A., Hunter, K., Irwin, N., Green, B. D., Greer, B., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.001 · Cited by 15 · see citing works

Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16)

Irwin, N., Green, B. D., Parker, J. C., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.03.006 · Cited by 15 · see citing works

Evaluation of the long-term effects of gastric inhibitory polypeptide–ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice

Irwin, N., Montgomery, I. A., & Flatt, P. R. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114511005228 · Cited by 13 · see citing works

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabeticob/obmice

O'Harte, F. P. M., Hunter, K., Gault, V. A., Irwin, N., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2006 · Cited by 12 · see citing works

Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice

McShane, L. M., Irwin, N., O’Flynn, D., Franklin, Z. J., Hewage, C. M., & O'Harte, F. P. M. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0463 · Cited by 12 · see citing works

RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes

Gault, V. A. (2017) · Diabetic Medicine · doi:10.1111/dme.13522 · Cited by 12 · see citing works

Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus

Xiong, S., Cao, J., Liu, X., Deng, X.-M., Liu, Z., & Zhang, F. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/625196 · Cited by 11 · see citing works

Inhibition of GIP signaling extends lifespan without caloric restriction

Hoizumi, M., Sato, T. K., Shimizu, T., Kato, S., Tsukiyama, K., Narita, T., Fujita, H., Morii, T., Sassa, M. H., Seino, Y., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.036 · Cited by 10 · see citing works

The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update

Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works

The carbohydrate-insulin model: A physiological perspective on the obesity pandemic

Ludwig, D. S., Aronne, L. J., Astrup, A., de Cabo, R., Cantley, L. C., Friedman, M. I., Heymsfield, S. B., Johnson, J. D., King, J. C., Krauss, R. M., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab270 · Cited by 292 · see citing works

Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance

De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17 · see citing works

Determinant of postprandial triglyceride levels in healthy young adults

Tarigan, T. J. E., Khumaedi, A. I., Wafa, S., Johan, M., Abdullah, M., SURONO, I. S., & Tahapary, D. L. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.027 · Cited by 9 · see citing works

[Postprandial hyperglycemia].

Perusicová, J. (2003) · PubMed

Novel aspects of postprandial lipemia in relation to atherosclerosis

Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.007 · Cited by 94 · see citing works

Exercise and Dietary-Mediated Reductions in Postprandial Lipemia

Plaisance, E. P., & Fisher, G. (2014) · Journal of Nutrition and Metabolism · doi:10.1155/2014/902065 · Cited by 33 · see citing works

Characterization of postprandial blood pressure and pulse pressure in essential hypertension and type 2 diabetes milltus

ZHU, Z. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02779-6